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Surgery for Cardiac Tumors (Primary and Secondary) – Clinical
Experience and Surgical Results in 22 Patients: Queen Elizabeth
Hospital
KAR-WAI LAM,1 CHAN-CHUNG MA,1 KWOK-KEUNG HO,1 CHEUNG-WAH CHENG,2 KAM-TIM CHAN2
From 1Department of Cardiothoracic Surgery; 2Cardiology Division, Department of Medicine, Queen Elizabeth
Hospital, Hong Kong
LAM ET AL.: Surgery for Cardiac Tumors (Primary and Secondary) – Clinical Experience and Surgical Results
in 22 Patients: Queen Elizabeth Hospital. Purpose: Retrospective review of surgical management of the 22 cardiac
tumors resected in Queen Elizabeth Hospital during the period of March 1995-December 2002. Methods: Presenting
symptoms, diagnostic data, anatomical findings, surgical techniques, morbidity and complications of surgery were
recorded. Follow up data was retrieved from out-patient records. Results: There were 12 male (54.5%) and 10
female (45.4%) patients. Median age was 61. 50% (11/22) of the cases were myxoma. Of the remaining cases, 27.3%
(6/22) were various types of secondary metastastic tumor, 13.6% (3/22) were tumor of mediastinum with cardiac
invasion, and 9.1% (2/23) were primary malignancy. Left sided masses were dominated by myxoma, which were
sited either on the inter-atrial septum (81.8%) or left atrium (18.1%). All other tumor groups were found on the right
side. Dyspnea (81.9%) was the most common presenting symptom, followed by chest pain (31.8%), embolic events
(13.6%) and superior vena cava obstruction. All tumors were resected with cardiopulmonary bypass under moderate
hypothermia, undertaken via either right atriotomy, superior septal and trans-septal with full thickness excision. The
average cross-clamp time and bypass time were 48.6 minutes and 101.4 minutes respectively. The average blood
loss was 813 ml. Post-operatively, 2 of the cases were complicated by junctional bradycardia and one of them
required permanent pacing. Other complications including pericardial effusion, superior vena cava obstruction,
pneumonia, secondary hemorrhage had been reported. The average follow up period was 40 months ranging from
3 months to 8 years. All patients with primary benign myxoma remained asymptomatic except one died 3 years after
surgery. This patient had known co-existing history of breast cancer. She suffered from embolic complications and
finally succumbed from multiple organ failure. All patients with secondary neoplasms died during the course of
follow-up. One with germ cell tumor was lost to follow up. Survival for primary benign tumors and cardiac metastasis
from secondary tumors, were 34 and 6 months respectively. The median survival of all tumors was 25 months.
Surgical resection, when possible, is the treatment of choice for all patients with cardiac neoplasms. It is curative in
benign tumors. On the other hand, palliative surgical procedures may be carried out for malignant tumors for relief
of obstructive symptoms and allow time for adjuvant therapy. (J HK Coll Cardiol 2004;12:7-15)
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Introduction
Primary cardiac tumor is rare entities.1 Three
quarters of tumor are benign and nearly half of the
benign tumors are myxoma. Metastatic tumor
component, on the other hand, is relatively frequent. It
is generally located in the pericardium.1 Diagnosis is
usually difficult since clinical manifestations varied and
sometimes patients may be asymptomatic. Surgical
results in patients with primary cardiac tumors depend
upon the anatomical and histological type of tumors.
Conduction disturbances and supra-ventricular
arrhythmias are common complications following
excision of left atrial myxomas. Superior-septal
approach can injure sinus node function because incision
interrupts the sinus node artery.2 Benign cardiac tumors
are generally curable if surgically excised, and the
prognosis is excellent. Aggressive surgery can palliate
obstructive symptoms in malignant tumors and allow
time for adjuvant therapy even though it may result in
incomplete excision.3

Patients and Methods
Cardiac tumors (primary and secondary) were
resected from 22 patients in Queen Elizabeth Hospital
between the period of March 1995-December 2002.
There were 12 male (54.5%) and 10 female (45.5%)
patients (age between 14-72). Median age was 61 and
mean age was 56.7.
Tumors were mainly divided into 3 groups:
primary (benign and malignant), secondary (metastatic)
and mediastinal tumor with cardiac invasion. Primary,
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benign cardiac tumor, myxoma (n=11), accounted for
50% of all cases. Primary malignant composed of 9%
of all cases. One of them was angiosarcoma (n=1) and
the other malignant fibrous histiocytoma (n=1). Of the
secondary cardiac tumors, 3 were metastasis from
carcinoma of lung (13.6%), including one large cell
carcinoma and 2 non-small cell carcinoma. In the
remaining cases, 2 were metastasis from the liver
(hepatocellular carcinoma) and one from the bladder
(transitional cell carcinoma). Lastly, the mediastinal
group with cardiac invasion accounted for 13.6%, of
all which 2 were malignant thymoma (n=2) and one
germ cell tumor (n=1) (Tables 1 & 2).

Presenting Symptom
The majority (81.8%) of patients presented with
shortness of breath and chest pain (31.8%). Embolic
events (including recurrent TIA and pulmonary
embolus) were noted in 3 patients (13.6%). One of the
pulmonary embolus was located in the right pulmonary
artery with extension into the right ventricle. Three of
the patients presented with Superior Vena Caval
Obstruction (SVCO) syndrome. Various cardiopulmonary symptoms (including dizziness, cough,
hemoptysis and fever) had been reported (Table 3).

Investigation
All patients had echocardiogram (transthoracic)
as their diagnostic modalities. Transoesophageal
echocardiogram and CT thorax were performed in
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Table 1. Results (primary cardiac tumor)
Lesion
Myxoma
Malignant fibrous histiocytoma
Angiosarcoma
LA: left atrium; RA: right atrium

No
11
1
1

(benign)
(malignant)
(malignant)

Sex (M/F)
3/8
0/1
1/0

Site
LA (2), interatrial septum (9)
LA
RA

Table 2. Results (secondary / metastasis)
Lesion
Mediastinal

No
2
1

Sex (M/F)
2/0
1/0

Site
Thymoma / thymic CA
Thymus
Germ cell
Mediastinal with bilateral pleural extension, right
bronchus and trachea
Secondary
HCC
2
2/0
RV, IVC
TCC
1
1/0
RA
Lung CA
3
2/1
RV, LA, RVOT
CA: cancer; HCC: hepatocellular carcinoma; TCC: transitional cell carinoma; RV: right ventricle; IVC: inferior vena cava; RA:
right atrium, AV: atrio-ventricular; RVOT: right ventricular outflow tract

Table 3. Clinical presentations
Symptom
Dyspnea
CHF
Chest pain
Syncope
Embolism

Cerebral
Peripheral
Coronary
AII 3

Myxoma
8/11 (72.7%)
4/11 (36.3%)
5/11 (45.4%)
0
1/11 (9.09%)
0
1/11 (9.09%)

Primary malignant
2/2 (100%)
1/2 (50%)
1/2 (50%)
0
0
0
0
0
1 (hemoptysis)

Constitional
3/11 (27.2%)
manifestation
SVCO
0
0
CHF: congestive heart failure; SVCO: superior vena caval obstruction

selected patients. One patient with history of ischemic
heart disease also had coronary angiogram as part of
the preoperative investigation (Figure 1).
Tumor size range from 2.5 x 5 cm to 7-8 cm x 5.5
cm in size. Of all the atrial myxoma, 4 had narrow stalk
and one was pedicled. Two had broad sessile base. For
the non-myxomatous tumor group, only one of them
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Secondary malignant
5/6 (83.3%)
1/6 (16.7%)
1/6 (16.7%)
0
0
2/6 (33.3%)
0
0
0

Mediastinal tumor
3/3 (100%)
0
0
0
0
0
0
0
0

0

3/3 (100%)

had narrow stalk. One patient had tumor arising from
the pulmonary valve annulus (Figures 2 & 3).
In each case, tumor was excised during total
cardiopulmonary bypass under moderate hypothermia.
The average cross-clamp time and bypass time were
48.6 minutes and 101.4 minutes respectively. The
average blood loss was 813 ml.
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Tumor size: range from 2.5 x 5 cm to 7-8 cm x 5.5 cm in size
(echocardiogram)

Surgical approaches were mainly accessed via
the right atrium (right atriotomy). Amongst these 17
cases, superior-septal approach was employed in 6 of
the cases. Trans-septal approach was used in 3 cases.
One of them required the extension of incision into the
left atrium. Another required incision into pulmonary
artery because of the extent of the tumor mass.
Tumor excision was performed in 17 cases and
the remaining 5 were performed as palliative procedures
(Figures 4 & 5).
Excision of the atrial tumor with an adequate
margin was generally performed in each of these cases.
Atrial septal defect (ASD) was created in 5 of these
cases, in which 2 of them required patch repair. Primary
closure (of ASD) was performed in the remaining case.
One patient also had co-existing mitral valve
replacement (Figure 6 & Table 4).

Figure 1. Diagnostic modalities.

Figure 2. Morphology of tumor masses.
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Figure 3. Site and distribution of tumor.

Figure 4. Surgical procedures.

Figure 5. Surgical approaches.
J HK Coll Cardiol, Vol 12
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Figure 6. Type of surgery (treatment group: tumor excision).

bleeding. The third patient with angiosarcoma died
of multi-organ failure and sepsis (due to the rapid
progression of the disease) (Table 5).
Recurrence had been reported in 2 patients.
One with malignant fibrous histiocytoma and large
cell carcinoma (lung), in which both received cycles
of chemotherapy. The tumor size were large and in
conjunction with its aggressive nature and rapid
growth, debulking surgery had been performed for
palliative purposes.

Table 4. Early morbidity
• Cardiac complications
- Junctional bradycardia
- Pericardial effusion
• Respiratory complications
- Pneumonia
• Thoracic complications
- SVCO obstruction
- Bilateral diaphagmatic paralysis
• Systemic complications
- Secondary hemorrhage
- Wound infection
- Sepsis
- GI bleeding
- Hypoxic brain damage
- Multi-organ failure/DIC
- Embolic events

2
1
1
1
1
1
1
1
2
1
1
1

Follow up
All 12 survivors (10 myxoma, 1 thymic
carcinoma and 1 malignant thymoma) remained
asymptomatic during the time of follow-up of up to
7 years. One patient with germ cell tumor was lost to
follow-up.

Early Deaths
Early deaths were defined as death within 30
days of operation which occurred in 3 of our patients.
One of them (with secondary metastasis from
transitional cell carcinoma) died of complications as
a result of tumor obstruction to the right ventricular
outflow tract. The second patient (carcinoma of
unknown origin, ? lung) died of gastrointestinal
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Discussion
Tumors of the heart remain a rare occurrence.
The incidence of primary cardiac neoplasia ranges
from 0.001% to 0.03% in autopsy report.4
In adult, approximately 75% of such tumors
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Table 5. Late deaths
Tumor type

Sex/age

Large cell carcinoma
HCC

M/58
M/62

Time from presentation
till death
5 months
6 months

HCC
MFH

M/62
F/64

6 months
2 years

Evidence of recurrence

Cause of death

Malignant pleural effusion
(FU PWH)

Large cell CA
Palliative resection of
tumor (RVOTO)
Progression of RHF
HCC, RHF
Progression of CHF
Disseminated CA

Palliative resection of tumor
Yes (LA wall with
obstruction to MV valve
prosthesis)
Secondary cell
M/59
3 years
Intraperitoneal metastatic
CA lung
carcinoma (lung)
spread
Myxoma
F/59
3 years
Emboli (recurrent TIA,
Sepsis, MOF
(background history
popliteal and femoral artery
of CA breast)
thrombosis) septic
encephalopathy
CA: cancer; HCC: hepatocellular; MFH: malignant fibroblastic histiocytoma; RHF: right heart failure; CHF: congestive heart
failure; TIA: transient ischemic attack; MOF: multi-organ failure

are benign and 25% are malignant.5 Eleven of 22 (50%)
tumors in this surgical series were benign tumor and
all were myxoma. Two (9.1%) were primary
malignant tumors (Figure 1). In the remaining 8 cases
were metastatic tumor (arising from lung, liver and
bladder). 3/22 (13.6%) were mediastinal tumor with
cardiac invasion (Figure 2).
Myxoma is the most common primary tumor
of the heart (30-50% of all cases). They may affect
patients of all ages, predominantly women. They are
gelatinous masses (myxomatous), lobulated, attached
to the endocardium via a variable sized pedicle or by
a wide base that project toward the interior of the
cavity without infiltrating the underlying tissue. 7580% are found in the left atrium, especially associated
to the fossa ovalis.3
Sarcoma accounted for almost all these
malignant tumors, they have a rapid and fatal
evolution. Surgical statistics show that the most
frequent malignant tumors are angiosarcoma (3540%), most of which (80%) are located in the right
atrium.1 They are invasive tumor masses, with areas
of necrosis and hemorrhage affecting the
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myocardium, and may protrude into the atrial cavity.
Because of its unique location, they can manifest as
right heart failure. Pericardial effusion (usually
hemorrhagic in nature with or without tamponade)
as well as systemic manifestation (e.g. fever, weight
loss) had also been reported in the literature.1
The only patient with angiosarcoma (primary
malignant) in our series, the tumor was also sited in
the right atrium. He presented acutely with marked
shortness of breath and hemoptysis. His condition
deteriorated rapidly despite palliative surgical
resection of the tumor. He went on to develop multiorgan failure, septicaemic shock and eventfully died
the next day after surgery.
Secondary cardiac neoplasms are 20-40 times
more common compared with primary malignancies.3
Metastases can reach the heart via blood stream and
coronary arteries (e.g. melanoma, sarcoma and
bronchogenic carcinoma). Other routes include the
lymphatic channels or direct invasion of tumor from
adjacent lung, breast, oesophagus and thymus.
Pericardium is the most frequently involved structure
through direct invasion by various thoracic tumors.
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Clinical symptoms were commonly reported to
be found in 10% of these patients6 Pericardial effusion
or cardiac tamponade was the most common symptom.
Three of our patients (with mediastinal tumor) presented
with symptoms of superior vena cava obstruction.
Abdominal and pelvic tumors may grow in a
cephalad direction via the inferior vena cava to reach
the right atrium. Up to ~10% of cases of renal cell
carcinoma behave in this manner and nearly 40% of
these reach the right atrium.3

Surgical Approaches
Various approaches had been described in the
literature, depending on the site and extent of tumor
involvement. The superior-septal approach (SS) had
been adopted in the majority of the cases, however,
trans-septal approach (TS) had also been used
depending on the location of the tumor.
The proposed advantages of TS include only
one atrial incision, adequate exposure for evaluation
of the mitral valve, low recurrence rates and its long
term efficacy. 7 The SS, on the other hand, provides
an excellent exposure for en bloc removal of the
tumor with simultaneous visualization of both sides
(right and left) of the inter-atrial septum. It is
associated with a lower risk of damaging the mass
and thus tumor embolisation.
Supra-ventricular arrhythmias and conduction
disturbances were commonly reported following this
approach, as the sinus nodal artery is often interrupted
during the incision and thus sinus nodal function.2
In our series, 3 cases of post-operative
arrhythmia had been reported. Two of them were
junctional bradycardia and the SS approach had been
adopted in these cases. One required temporary
pacing which subsequently self-reverted to sinus
rhythm. The third patient had complete heart block
prior to operation (likely relating to tumor invasion
of the conduction system), she sustained such rhythm
post-operatively, which lately required permanent
pacing for treatment of her condition. The prognosis
for resection of atrial myxoma, as repetitively
reported in the literature, has been excellent. The
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optimal operative approach lacks uniformity. There
is still considerable controversy concerning the extent
of surgical resection necessary to prevent recurrence.5
The rate of recurrence had been reported to be
between 4-7% in different series.5,8 In our series, only
one patient with myxoma died 3 years after surgical
treatment. She suffered from complications
(including septic encephalopathy and multi-organ
failure) likely relating to her past history of breast
cancer. During the course of her follow-up, there had
been no evidence of recurrence of myxoma.
Post-operative echocardiogram had been
generally recommended to detect recurrence. Except
for those patients with multiple, atypical or familial
myxoma, few trans-thoracic echocardiogram at 5year intervals throughout life should be adequate if
there has been recurrence in the first few years.9
On the other hand, prognosis is generally poor
in those with primary malignant or secondary
neoplasms. Surgical treatment is directed at providing
symptomatic relief with minimal patient discomfort
and hospital stay. 3 All patients with secondary
neoplasms died after a period of follow-up ranging
between 3 months to 3 years.
In conclusion, surgical resection, when
possible, is the treatment of choice for all patients
with cardiac neoplasms. It is curative in benign
tumors. Palliative procedures, on the other hand, may
be carried out for malignant tumors for relief of
obstructive symptoms. It may prolong life and allow
time for effective adjuvant therapy, but this would
depend on the histological type (thus natural behavior
of the tumor) and the location of the lesion.
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